KUALA LUMPUR, 22 December 2020 - HWGB Biotech Sdn Bhd (“HWGB Biotech”), a wholly owned subsidiary of Ho Wah Genting Berhad (“HWGB” or the “Company”) (Bursa Stock Code: 9601), today announced E-MO Biology Inc.’s abbreviated clinical study report on Phase 4 Clinical Trial. HWGB’s joint venture partner, US-based E-MO Biology Inc. (“EBI”), had completed the first stage study of Phase 4 clinical trial for providing a safe, effective, affordable and easy-to-compliant vaccine to utilize against COVID-19.
The serological evaluation had shown 100% (percent) of the subjects post-IPV immunization have developed specific antibodies in their blood samples after inoculation that recognized both poliovirus RdRp and SARS-Cov-2 RdRp and not adverse event or side effect was reported throughout the study period.
Managing Director of EBI, Dr. Xie QiYi, said: “By completing the first stage of the study, it has provided us with a lot of insight on the vaccine and its reaction to the COVID-19 virus, thus we are one step closer to provide a safe, affordable and easily administered vaccine to the public”.
“Furthermore, this vaccine has been widely used by children worldwide with proven safety profile. This is the only vaccine for COVID-19 that has been tested in children and could be either taken orally as a solution and also by injection”.
Ho Wah Genting Berhad (“HWGB” or the “Company”) is principally engaged in investment holdings and the provision of management services to its subsidiaries. The Company had on 30 June 2020 diversified its existing businesses to include healthcare-related industry which mainly involved in Health Supplement, Biotechnology and Health Technology. In addition, the Company and its subsidiaries (“HWGB Group” or the “Group”) are also engaging in the businesses of Investment holdings; manufacturing of wires and cables and moulded power supply cord sets and cable assemblies for electrical and electronic devices and equipment; Trading of wires and cables; and travel agent and tour related services.
HWGB Biotech Sdn Bhd, was incorporated on 18 June 2012 under the Companies Act, 1965 under the former name of HWG Consortium Sdn Bhd and changed to its current name on 22 May 2020. HWGB Biotech is principally involved in the distribution of all kinds of biotechnology products, bioinformatics diagnostic tools, all medical engineering equipment along with software developments and tools as well as to patent all original products and by-products, technologies and software developed or sourced by the company.
For more information about HWGB Biotech, follow us on https://hwgbbiotech.com, http://subscription.hwgbbiotech.com, Facebook, LinkedIn, and Telegram to view the latest updates about our company ventures in the healthcare industry.
Please refer to the US Food and Drug Administration website for more information on EBI’s Phase IV clinical study: https://www.clinicaltrials.gov/ct2/show/NCT04639375
E-Mo Biology Inc (“EBI”) was incorporated in the state of California in the United States of America on 24 May 2020. It is principally involved in conducting biology research and development activities and is the sponsor of a study which indicates booster polio vaccine to reduce Covid-19 SARS-COV-2 infection and severity.
EBI is founded by Dr. Xie QiYi, who serves as its Managing Director of EBI. He has over 30 years of experience in areas of public health and infection disease control. He was also involved in the development of medical and diagnostic devices, with focus on Quality, Regulatory and Clinical Affairs for quality systems.